Vigilant Biosciences Closes $2M Series A Round


Vigilant Biosciences, a Miami biotech startup commercializing an oral rinse for oral cancer screening based on technology licensed from the University of Miami, has closed an oversubscribed $2M Series A round investment. The company received $2.3M in total proceeds, including a $300K loan from the Florida Institute for the Commercialization of Public Research Seed Capital Acceleration Program. “Our investors recognize the immense and compelling opportunity for our products in both developed and developing countries,” said Matthew H.J. Kim, Founder, Chairman, and CEO of Vigilant. Both of Kim’s parents are oral cancer survivors. “Our products address critical needs in multiple markets and different healthcare environments…needs that have gone unmet for far too long.” Proceeds will support 510(k) clearance and CE Mark approval efforts while enabling the company to prepare for international product launch and to simultaneously advance other products in its pipeline. Vigilant’s initial development-stage products include low-cost, oral cancer-specific risk assessment kits. These kits provide immediate and simple color changes in the presence of certain levels of proteins clinically proven to be associated with early-onset of oral cancer – typically before a lesion is visually detected. The test can be applied to every adult, with particular emphasis on tobacco users, those who consume alcohol, and people with human papillomavirus (HPV) – collectively representing a $1B U.S. market opportunity and a multi-billion dollar opportunity worldwide. Read more here.